Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice:: Requirement for CD4+ T lymphocytes

被引:317
作者
Overwijk, WW
Lee, DS
Surman, DR
Irvine, KR
Touloukian, CE
Chan, CC
Carroll, MW
Moss, B
Rosenberg, SA
Restifo, NP
机构
[1] NCI, Surg Branch, Bethesda, MD 20892 USA
[2] NEI, Immunol Lab, Bethesda, MD 20892 USA
[3] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1073/pnas.96.6.2982
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many human and mouse tumor antigens are normal, nonmutated tissue differentiation antigens, Consequently, immunization with these "self" antigens could induce autoimmunity. When we tried to induce immune responses to five mouse melanocyte differentiation antigens, gp100? MART-1, tyrosinase, and tyrosinase-related proteins (TRP) 1 and TRP-2, we observed striking depigmentation and melanocyte destruction only in the skin of mice inoculated with a vaccinia virus encoding mouse TRP-1, These mice rejected a lethal challenge of B16 melanoma, indicating the immune response against TRP-1 could destroy both normal and malignant melanocytes. Cytotoxic T lymphocytes specific for TRP-1 could not be detected in depigmented mice, but high titers of Ige anti-TRP-l antibodies were present, Experiments with knockout mice revealed an absolute dependence on major histocompatibility complex class II, but not major histocompatibility complex class I, for the induction of both vitiligo and tumor protection. Together, these results suggest that the deliberate induction of self-reactivity using a recombinant viral vector can lead to tumor destruction, and that in this model, CD4(+) T lymphocytes are an integral part of this process. Vaccine strategies targeting tissue differentiation antigens may be valuable in canters arising from nonessential cells and organs such as melanocytes, prostate, testis, breast, and ovary.
引用
收藏
页码:2982 / 2987
页数:6
相关论文
共 48 条
  • [1] A range of CD4 T cell tolerance: Partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis
    Akkaraju, S
    Ho, WY
    Leong, D
    Canaan, K
    Davis, MM
    Goodnow, CC
    [J]. IMMUNITY, 1997, 7 (02) : 255 - 271
  • [2] BARTH RJ, 1990, J IMMUNOL, V144, P1531
  • [3] Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
    Bloom, MB
    PerryLalley, D
    Robbins, PF
    Li, Y
    ElGamil, M
    Rosenberg, SA
    Yang, JC
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) : 453 - 459
  • [4] Tumor antigens recognized by T cells
    Boon, T
    Coulie, PG
    VandenEynde, B
    [J]. IMMUNOLOGY TODAY, 1997, 18 (06): : 267 - 268
  • [5] Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
    Bronte, V
    Carroll, MW
    Goletz, TJ
    Wang, M
    Overwijk, WW
    Marincola, F
    Rosenberg, SA
    Moss, B
    Restifo, NP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (07) : 3183 - 3188
  • [6] Compact, synthetic, vaccinia virus early/late promoter for protein expression
    Chakrabarti, S
    Sisler, JR
    Moss, B
    [J]. BIOTECHNIQUES, 1997, 23 (06) : 1094 - 1097
  • [7] Christianson GJ, 1997, J IMMUNOL, V159, P4781
  • [8] De Silva HD, 1998, IMMUNOLOGY, V93, P405
  • [9] DI RF, 1996, J EXP MED, V183, P2153
  • [10] Earl P.L., 1991, Current Protocols in Molecular Biology, p16.16.1